You are here

Closed

Reset

NOTE: The Solicitations and topics listed on this site are copies from the various SBIR agency solicitations and are not necessarily the latest and most up-to-date. For this reason, you should visit the respective agency SBIR sites to read the official version of the solicitations and download the appropriate forms and rules.

  1. 313: RNAi Cancer Therapeutics using Nanotechnology

    Release Date: 08-15-2012Open Date: 08-15-2012Due Date: 12-03-2012Close Date: 12-03-2012

    In 2011, the SBIR Development Center hosted an industry roundtable to solicit inputs from life science industry professionals on emerging areas that are ripe for technology development by the small business community. Participants at this meeting expressed strong interest in using the SBIR mechanism to foster and encourage the development of novel RNA interference (RNAi) delivery platforms, partic ...

    SBIRPhase IDepartment of Health and Human Services
  2. 314: Development of Human Tissue Culture Systems that Mimic the Tumor Microenvironment

    Release Date: 08-15-2012Open Date: 08-15-2012Due Date: 12-03-2012Close Date: 12-03-2012

    There is a critical need to improve the accuracy of preclinical drug efficacy screening and testing through the development of in vitro culture systems that more effectively mimic the in vivo environment. Currently, two-dimensional (2D) in vitro culture systems or in vivo animal models are the primary tools used to test cancer cell responses to drugs. However, drug sensitivity data obtained via 2D ...

    SBIRPhase IDepartment of Health and Human Services
  3. 315: Development of Companion Diagnostics: Enabling Precision Medicine in Cancer Therapy

    Release Date: 08-15-2012Open Date: 08-15-2012Due Date: 12-03-2012Close Date: 12-03-2012

    The demand for companion diagnostics has greatly increased with the recognition that matching the right patient to the right drug at the right time can improve patient care and may decrease health care costs. More than a dozen companion diagnostic tests have been approved by the FDA to guide the prescription of products in oncology, cardiovascular disease, and infectious disease. Among them, tests ...

    SBIRPhase IDepartment of Health and Human Services
  4. 316: Development of CTC Isolation Technologies Enabling Downstream Single Cell Molecular Analysis

    Release Date: 08-15-2012Open Date: 08-15-2012Due Date: 12-03-2012Close Date: 12-03-2012

    Summary Circulating tumor cells (CTCs) are cancer cells shed from either the primary tumor or its metastases and are circulating in the peripheral blood. While metastases are directly responsible for the majority of cancer deaths, CTCs may constitute seeds for metastases and may be instrumental for the spread of the disease. Many studies have shown that the presence of CTCs in peripheral blood or ...

    SBIRPhase IDepartment of Health and Human Services
  5. 317: Wound Healing Preparations Incorporating Nitric Oxide-Releasing Materials (NIH Technology Transfer)

    Release Date: 08-15-2012Open Date: 08-15-2012Due Date: 12-03-2012Close Date: 12-03-2012

    Summary Non-healing wounds can pose significant problems for cancer patients (e.g., in cases where multiple operations are required for local recurrence, when large wounds are slow to close, and especially when patients receive radiation at sites requiring surgery). In addition, the effects of chemotherapy, nutritional deficits along with co-morbidities (e.g., diabetes), and infections can complic ...

    SBIRPhase IDepartment of Health and Human Services
  6. 318: Test to Predict Effectiveness of Docetaxel Treatment for Prostate Cancer (NIH Technology Transfer)

    Release Date: 08-15-2012Open Date: 08-15-2012Due Date: 12-03-2012Close Date: 12-03-2012

    Summary Over the past two years, medical oncologists have added three new therapies to the therapeutic arsenal against Castration-Resistant Prostate Cancer (CRPC): abiraterone, Sipleucel-T, and cabazitaxel. Before approval of these agents, docetaxel was the only life-extending therapeutic option for men with CRPC, and docetaxel remains the standard of care for men who can tolerate chemotherapy. Mo ...

    SBIRPhase IDepartment of Health and Human Services
  7. 319: Technology to Generate Anti-Peptide Capture Reagents for Affinity-Enriched Proteomic Studies

    Release Date: 08-15-2012Open Date: 08-15-2012Due Date: 12-03-2012Close Date: 12-03-2012

    Summary Anti-peptide capture reagents can be used to identify and quantify proteins containing a target peptide sequence with a number of applications in biological research and bioassay development. For instance, they are used routinely in techniques such as immunoprecipitation, Western blot, and immunohistological identification and protein localization. A recently-developed application of such ...

    SBIRPhase IDepartment of Health and Human Services
  8. 320: High Quality Cancer-Related Standards for Metabolomics Research

    Release Date: 08-15-2012Open Date: 08-15-2012Due Date: 12-03-2012Close Date: 12-03-2012

    Summary The metabolome is a measure of the output of biological pathways and, as such, is often considered more representative of the functional state of a cell than other ‘omics measures such as genomics or proteomics. In addition, metabolites are conserved across various animal species, facilitating the extrapolation of research findings in laboratory animals to humans. Despite early promise, ...

    SBIRPhase IDepartment of Health and Human Services
  9. 321: Chemically Defined Glycan Libraries for Reference Standards and Glycomics Research (Joint NCI-NIGMS Program)

    Release Date: 08-15-2012Open Date: 08-15-2012Due Date: 12-03-2012Close Date: 12-03-2012

    Summary Glycans play important roles in cell recognition, motility, signaling processes, cell differentiation, cell adhesion, microbial pathogenesis, and immune recognition. Carbohydrate-based high throughput assays (e.g. glycan microarrays, nanoparticles) hold great promise for the rapid analysis of carbohydrate binding proteins (CBPs), elucidation of CBP biology, and the development of diagnosti ...

    SBIRPhase IDepartment of Health and Human Services
  10. 322: Real-Time Integration of Sensor and Self-Report Data for Clinical and Research Applications

    Release Date: 08-15-2012Open Date: 08-15-2012Due Date: 12-03-2012Close Date: 12-03-2012

    Summary Wireless sensors, and mobile devices and applications are increasingly marketed for health monitoring or interventions in consumer and clinical settings for prevention or management of chronic disease. A rapidly expanding market segment of technologies are focused on objective measures of health related behaviors (e.g., physical activity, sleep, diet, medication adherence, etc.). These mob ...

    SBIRPhase IDepartment of Health and Human Services
US Flag An Official Website of the United States Government